CN114072402A - 作为fgfr和vegfr双重抑制剂的吡啶衍生物 - Google Patents

作为fgfr和vegfr双重抑制剂的吡啶衍生物 Download PDF

Info

Publication number
CN114072402A
CN114072402A CN202080047757.XA CN202080047757A CN114072402A CN 114072402 A CN114072402 A CN 114072402A CN 202080047757 A CN202080047757 A CN 202080047757A CN 114072402 A CN114072402 A CN 114072402A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
compound according
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080047757.XA
Other languages
English (en)
Other versions
CN114072402B (zh
Inventor
陈正霞
戴美碧
张杨
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cgenetech Suzhou China Co Ltd
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN114072402A publication Critical patent/CN114072402A/zh
Application granted granted Critical
Publication of CN114072402B publication Critical patent/CN114072402B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

一种FGFR和VEGFR双重抑制剂，具体为式(I)所示化合物或药学上可接受的盐。
Figure DDA0003440702810000011

Description

PCT国内申请，说明书已公开。

Claims (18)

  1. PCT国内申请，权利要求书已公开。
CN202080047757.XA 2019-07-26 2020-07-24 作为fgfr和vegfr双重抑制剂的吡啶衍生物 Active CN114072402B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2019106842523 2019-07-26
CN201910684252 2019-07-26
CN201911266249 2019-12-11
CN2019112662496 2019-12-11
CN2020102304933 2020-03-27
CN202010230493 2020-03-27
PCT/CN2020/104550 WO2021018047A1 (zh) 2019-07-26 2020-07-24 作为fgfr和vegfr双重抑制剂的吡啶衍生物

Publications (2)

Publication Number Publication Date
CN114072402A true CN114072402A (zh) 2022-02-18
CN114072402B CN114072402B (zh) 2023-12-26

Family

ID=74229365

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080047757.XA Active CN114072402B (zh) 2019-07-26 2020-07-24 作为fgfr和vegfr双重抑制剂的吡啶衍生物

Country Status (8)

Country Link
US (1) US20220267324A1 (zh)
EP (1) EP4006027A4 (zh)
JP (1) JP7300057B2 (zh)
KR (1) KR20220052939A (zh)
CN (1) CN114072402B (zh)
AU (1) AU2020320997B2 (zh)
CA (1) CA3145680C (zh)
WO (1) WO2021018047A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4286382A1 (en) * 2021-01-26 2023-12-06 CGeneTech (Suzhou, China) Co., Ltd. Crystal form of methylpyrazole-substituted pyridoimidazole compound and preparation method therefor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008078091A1 (en) * 2006-12-22 2008-07-03 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
CN101827844A (zh) * 2007-10-17 2010-09-08 诺瓦提斯公司 可用作ALK抑制剂的咪唑并[1,2-a]吡啶衍生物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2121687T3 (pl) 2006-12-22 2016-03-31 Astex Therapeutics Ltd Pochodne amin tricyklicznych jako inhibitory białkowej kinazy tyrozynowej
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
JP2011530511A (ja) 2008-08-05 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 治療用化合物
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
PT2872491T (pt) 2012-07-11 2021-08-05 Blueprint Medicines Corp Inibidores do recetor do fator de crescimento de fibroblastos
TWI628176B (zh) 2013-04-04 2018-07-01 奧利安公司 蛋白質激酶抑制劑
WO2018172616A1 (en) 2017-03-23 2018-09-27 Orion Corporation Process for the preparation of a sulfonamide structured kinase inhibitor
CN113490667B (zh) * 2018-12-29 2023-10-27 盛世泰科生物医药技术(苏州)股份有限公司 作为fgfr和vegfr双重抑制剂的咪唑并吡啶衍生物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008078091A1 (en) * 2006-12-22 2008-07-03 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
CN101827844A (zh) * 2007-10-17 2010-09-08 诺瓦提斯公司 可用作ALK抑制剂的咪唑并[1,2-a]吡啶衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GOEL.R.等: "Imidazo [1,2-a] pyridines: Promising Drug Candidate for Antitumor Therapy", 《CURRENT TOPICS IN MEDICINAL CHEMISTRY》, vol. 16, no. 30, pages 3590 - 3616, XP055777079, DOI: 10.2174/156802661666616041 *

Also Published As

Publication number Publication date
WO2021018047A1 (zh) 2021-02-04
KR20220052939A (ko) 2022-04-28
AU2020320997A1 (en) 2022-03-10
JP2022542163A (ja) 2022-09-29
US20220267324A1 (en) 2022-08-25
CA3145680A1 (en) 2021-02-04
EP4006027A4 (en) 2023-07-26
CN114072402B (zh) 2023-12-26
CA3145680C (en) 2024-03-12
JP7300057B2 (ja) 2023-06-28
EP4006027A1 (en) 2022-06-01
AU2020320997B2 (en) 2023-07-27

Similar Documents

Publication Publication Date Title
CN104011052B (zh) 化合物
CN115335372B (zh) 八氢吡嗪并二氮杂萘啶二酮类化生物
US10548883B2 (en) Benzotriazole-derived α and β-unsaturated amide compound used as TGF-β RI inhibitor
CN105189456A (zh) Kras g12c的共价抑制剂
WO2019154365A1 (zh) 一种atr抑制剂及其应用
CN113490667B (zh) 作为fgfr和vegfr双重抑制剂的咪唑并吡啶衍生物
CN111542520B (zh) 作为a2a受体抑制剂的并环类衍生物
CN110799505B (zh) 用于治疗癌症、视网膜病症和心肌病的三取代嘧啶化合物和组合物
CN113993867B (zh) 作为fgfr和vegfr双重抑制剂的并环类化合物
WO2019154364A1 (zh) 作为fgfr抑制剂的吡嗪-2(1h)-酮类化合物
CN116761799A (zh) 嘧啶并吡喃类化合物
CN112601746B (zh) 吡唑并嘧啶衍生物及其作为pi3k抑制剂的应用
CN110023286A (zh) 作为ccr2/ccr5受体拮抗剂的联苯化合物
CN114072402A (zh) 作为fgfr和vegfr双重抑制剂的吡啶衍生物
CN113874379B (zh) 作为Cdc7抑制剂的四并环类化合物
CN113166055B (zh) 雌激素受体拮抗剂
CN111971285A (zh) 咪唑并吡咯酮化合物及其应用
JP7432739B2 (ja) アザインドール誘導体の結晶形及びその応用
WO2024002263A1 (zh) 氨基取代的杂芳基衍生物及其应用
CN115433179A (zh) 苯并嘧啶类化合物及其医药用途
CN114650991A (zh) 桥环并醛基吡啶衍生物及其应用
CN114805331A (zh) N连接的杂芳环类化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220706

Address after: 215123 Room 101, C11 / F, bio nano Park, 218 Xinghu street, Suzhou Industrial Park, Suzhou City, Jiangsu Province

Applicant after: CGENE TECH (SUZHOU, CHINA) Co.,Ltd.

Address before: 210032 room 218, business office building, No.9 Gaoxin Road, Jiangbei new district, Nanjing City, Jiangsu Province

Applicant before: Nanjing Mingde New Drug Development Co.,Ltd.

CB02 Change of applicant information
CB02 Change of applicant information

Address after: 215123 units 101 and 102, C11 building, phase I project of biomedical industrial park, No. 218 Xinghu street, Suzhou Industrial Park, China (Jiangsu) pilot Free Trade Zone, Suzhou, Jiangsu Province

Applicant after: CGENE TECH (SUZHOU, CHINA) Co.,Ltd.

Address before: 215123 Room 101, C11 / F, bio nano Park, 218 Xinghu street, Suzhou Industrial Park, Suzhou City, Jiangsu Province

Applicant before: CGENE TECH (SUZHOU, CHINA) Co.,Ltd.

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40070084

Country of ref document: HK

CB02 Change of applicant information
CB02 Change of applicant information

Address after: 215123 units 101 and 102, C11 building, phase I project of biomedical industrial park, No. 218 Xinghu street, Suzhou Industrial Park, China (Jiangsu) pilot Free Trade Zone, Suzhou, Jiangsu Province

Applicant after: Shengshi Taike Biopharmaceutical Technology (Suzhou) Co.,Ltd.

Address before: 215123 units 101 and 102, C11 building, phase I project of biomedical industrial park, No. 218 Xinghu street, Suzhou Industrial Park, China (Jiangsu) pilot Free Trade Zone, Suzhou, Jiangsu Province

Applicant before: CGENE TECH (SUZHOU, CHINA) Co.,Ltd.

GR01 Patent grant
GR01 Patent grant